ViiV Healthcare Company
$38.7M 65,891 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals Inc. reported $39,181,235.63 across General Payments, Research, and Ownership to 19,104 physicians and teaching hospitals across 36,687 transactions.
- $39.2M Top 10% payer
- All-tracks total
- 36,687 Top 10% volume
- Transactions
- 19,104 Top 10% reach
- Recipients
- +$457.7K
- General Payments vs PY2023
Alnylam Pharmaceuticals Inc. reported $39,181,235.63 across all CMS Open Payments tracks (General + Research + Ownership) to 19,104 physicians and teaching hospitals in Program Year 2024 - ranking #58 of 1,925 reporting manufacturers (0.3% of the all-tracks industry total); General Payments alone were $6,505,436.41, averaging $2.1K per recipient.
How Alnylam Pharmaceuticals Inc.'s $39.2M all-tracks total breaks down
Alnylam Pharmaceuticals Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
A
98/100
Total payments
A
100/100
Transaction volume
A
100/100
Physician reach
A
100/100
Payment type diversity
A
90/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer alnylam-pharmaceuticals-inc Alnylam Pharmaceuticals Inc.
$39.2M · #58/1,925 · 0.3% industry · PY2024
- TOT $39.2M
- RANK #58
- SHARE 0.3%
- TXN 36,687
- RCP 19,104
- CAT 7
- GEN $6.5M
- ΔGEN +$457.7K
- TOP1 16.2%
- PY 2024
Volume peers
Nearest volume peer: ViiV Healthcare Company ($38.7M)
Alnylam Pharmaceuticals Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Alnylam Pharmaceuticals Inc.'s CMS-reported General Payments increased by $457.7K (+7.6%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: ALNYLAM PHARMACEUTICALS INC.PY2023: ALNYLAM PHARMACEUTICALS INC.PY2024: Alnylam Pharmaceuticals Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $6,047,708.24
- PY2024
- $6,505,436.41
What the Data Shows for Alnylam Pharmaceuticals Inc.
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Alnylam Pharmaceuticals Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
231 transactions worth $2.9M make "Consulting Fee" the top general-payment category in the 7-category breakdown below, 44.8% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 7 types of general payments, Alnylam Pharmaceuticals Inc.'s largest category was "Consulting Fee" at $2.9M - 44.8% of General Payments.
Alnylam Pharmaceuticals Inc. reports 7 general-payment categories - the top three are Consulting Fee (44.8%), Compensation for Services Other Than Consulting (34.0%), and Food and Beverage (8.5%). The remaining 4 categories make up 12.7% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Alnylam Pharmaceuticals Inc. divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $2.9M | 231 | 44.8% |
| Compensation for Services Other Than Consulting | $2.2M | 419 | 34.0% |
| Food and Beverage | $550.5K | 17,454 | 8.5% |
| Space Rental or Facility Fees | $421.6K | 104 | 6.5% |
| Travel and Lodging | $333.9K | 875 | 5.1% |
| Grant | $70.8K | 9 | 1.1% |
| Education | $598.48 | 12 | 0.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $2,782,449.53 (42.8%) of $6,505,436.41 in this company's General Payments records across 9,834 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Alnylam Pharmaceuticals Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Brigham And Womens Hospital
$1,050,759.48 across 6 reported transactions
- 2
Sushama Scalera
$488,887.50 across 10 reported transactions
- 3
Dennis Ausiello
$484,629.86 across 15 reported transactions
- 4
Margaret A Hamburg
$476,884.99 across 18 reported transactions
- 5
Arthur Decillis
$281,287.70 across 12 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Alnylam Pharmaceuticals Inc. ranks #58 of 1,925 by total payments (top 3% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,292 of 1,838 by HHI (bottom 30% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Insight Medical Systems, Inc. : $174.6K total payments, HHI 507
- CoapTech, Inc. : $4.0K total payments, HHI 506
- Otter Pharmaceuticals, LLC : $86.2K total payments, HHI 504
- Minerva Surgical, Inc : $53.9K total payments, HHI 503
- Sterilmed, Inc. : $263.8K total payments, HHI 500
- Merge Healthcare Incorporated : $6.9K total payments, HHI 499
- Alnylam Pharmaceuticals Inc. (this company) : $6.5M total payments, HHI 498
- Nxstage Medical, Inc. : $106.2K total payments, HHI 496
- Adaptive Biotechnologies Corporation : $462.3K total payments, HHI 495
- Iovance Biotherapeutics, Inc. : $114.7K total payments, HHI 489
- Arjo Inc. : $151.8K total payments, HHI 489
- Banner Life Sciences, LLC : $82.4K total payments, HHI 487
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Alnylam Pharmaceuticals Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Alnylam Pharmaceuticals Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Alnylam Pharmaceuticals Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Spinal Simplicity, LLC
$40.8M 4,988 recipients
Compare payment profiles
Boehringer Ingelheim International GmbH
$41.1M 2,203 recipients
Compare payment profiles
Exelixis Inc.
$37.1M 10,612 recipients
Compare payment profiles
Sanofi Pasteur Inc.
$42.5M 14,446 recipients
Compare payment profiles
Alexion Pharmaceuticals, Inc.
$34.7M 48,499 recipients
Compare payment profiles
Put this to use
Alnylam Pharmaceuticals Inc. ranks #58 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See where Alnylam Pharmaceuticals Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Alnylam Pharmaceuticals Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.